X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (54) 54
hiv infections - drug therapy (40) 40
male (38) 38
adult (37) 37
infectious diseases (36) 36
female (35) 35
index medicus (33) 33
immunology (26) 26
middle aged (26) 26
hiv (22) 22
pharmacology & pharmacy (19) 19
virology (19) 19
microbiology (15) 15
anti-hiv agents - adverse effects (14) 14
drug therapy, combination (14) 14
hiv infections - complications (14) 14
hiv-infected patients (14) 14
protease inhibitors (13) 13
pharmacokinetics (12) 12
tenofovir (12) 12
therapy (12) 12
aids/hiv (11) 11
anti-hiv agents - therapeutic use (11) 11
antiretroviral therapy (11) 11
rna, viral - blood (11) 11
adenine - analogs & derivatives (10) 10
atazanavir sulfate (10) 10
hepatitis c, chronic - drug therapy (10) 10
hiv infections - virology (10) 10
retrospective studies (10) 10
viral load (10) 10
genotype (9) 9
human immunodeficiency virus--hiv (9) 9
pyridines - therapeutic use (9) 9
research (9) 9
treatment outcome (9) 9
antiretroviral drugs (8) 8
antiviral agents - administration & dosage (8) 8
antiviral agents - therapeutic use (8) 8
drug therapy (8) 8
hepatitis c, chronic - complications (8) 8
liver (8) 8
prospective studies (8) 8
pyridines - adverse effects (8) 8
recombinant proteins (8) 8
ribavirin - therapeutic use (8) 8
adenine - adverse effects (7) 7
anti-hiv agents - administration & dosage (7) 7
drug interactions (7) 7
hepatitis (7) 7
hiv infections - blood (7) 7
hiv protease inhibitors - adverse effects (7) 7
human-immunodeficiency-virus (7) 7
oligopeptides - therapeutic use (7) 7
organophosphonates - adverse effects (7) 7
pharmacogenetics (7) 7
reverse-transcriptase inhibitors (7) 7
ribavirin - administration & dosage (7) 7
spain (7) 7
alleles (6) 6
anemia (6) 6
cd4 lymphocyte count (6) 6
disoproxil fumarate (6) 6
drug resistance (6) 6
fanconi-syndrome (6) 6
hiv protease inhibitors - therapeutic use (6) 6
oligopeptides - adverse effects (6) 6
polymorphism, genetic (6) 6
pyridines - administration & dosage (6) 6
pyridines - pharmacokinetics (6) 6
ribavirin - adverse effects (6) 6
ritonavir - administration & dosage (6) 6
active antiretroviral therapy (5) 5
adenine - administration & dosage (5) 5
antiviral agents - adverse effects (5) 5
atazanavir (5) 5
combination (5) 5
drug administration schedule (5) 5
drug monitoring (5) 5
expression (5) 5
genotypes (5) 5
health aspects (5) 5
hepatitis c (5) 5
hiv infection (5) 5
hiv infections - genetics (5) 5
hiv protease inhibitors - pharmacokinetics (5) 5
hiv/aids (5) 5
interferon-alpha - therapeutic use (5) 5
kidney tubules - drug effects (5) 5
lopinavir (5) 5
organophosphonates - administration & dosage (5) 5
polyethylene glycols - therapeutic use (5) 5
pyridines - blood (5) 5
ribavirin (5) 5
risk factors (5) 5
adenine - therapeutic use (4) 4
antiretroviral therapy, highly active (4) 4
antiviral agents (4) 4
association (4) 4
chronic hepatitis (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 12/2010, Volume 54, Issue 12, pp. 5242 - 5250
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 06/2009, Volume 48, Issue 11, pp. e108 - e116
Journal Article
Journal Article
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 10/2010, Volume 202, Issue 8, pp. 1185 - 1191
Journal Article
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 4/2007, Volume 195, Issue 7, pp. 973 - 979
Background. Most antiretrovirals are metabolized in the liver, and lower dosing could be advisable in patients with severe liver insufficiency. Methods. Plasma... 
HIV/AIDS | Cirrhosis | Antiretrovirals | Liver diseases | Liver | Chronic hepatitis | Fibrosis | Antivirals | AIDS | Pharmacokinetics | Blood plasma | TRANSIENT ELASTOGRAPHY | DIAGNOSIS | INFECTIOUS DISEASES | REVERSE-TRANSCRIPTASE INHIBITORS | COINFECTED SUBJECTS | METABOLISM | DISEASE | HEPATOTOXICITY | HUMAN-IMMUNODEFICIENCY-VIRUS | NEVIRAPINE | PROTEASE INHIBITORS | Hepatitis C, Chronic - pathology | Humans | Male | Nevirapine - therapeutic use | Benzoxazines | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Nevirapine - blood | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Oxazines - administration & dosage | Anti-HIV Agents - blood | Pyridines - therapeutic use | Severity of Illness Index | Pyridines - administration & dosage | Oligopeptides - blood | Ritonavir - administration & dosage | Ritonavir - blood | Lopinavir | Pyrimidinones - therapeutic use | Hepatitis C, Chronic - blood | Pyridines - blood | Pyrimidinones - blood | Oxazines - therapeutic use | Liver Cirrhosis - pathology | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Drug Monitoring | Nevirapine - administration & dosage | Oxazines - blood | Antiviral agents | Analysis | Physiological aspects | Plasma cells | Drug metabolism | Cystic fibrosis | Influence | HIV patients | Research | Hepatitis C
Journal Article
Journal Article
Journal Article
Therapeutics and Clinical Risk Management, ISSN 1176-6336, 2009, Volume 5, Issue 1, pp. 99 - 116
Atazanavir (ATV) is one of the latest protease inhibitors (PI) approved for the treatment of HIV infection. The drug has a relatively long-life (∼7 h) and... 
Atazanavir | HIV | Protease inhibitors | Drug resistance | Antiretroviral drugs | Human immunodeficiency virus--HIV | Mutation | protease inhibitors | drug resistance | atazanavir
Journal Article
AIDS, ISSN 0269-9370, 03/2009, Volume 23, Issue 6, pp. 689 - 696
Journal Article